Abstract 1164P
Background
Melanoma and renal cell carcinoma are common cancers with growing incidence rates. Nivolumab, anti-programmed-death 1 protein (PD1) antibody selectively blocks the interaction between PD-1 and its ligand PD-L1 and enables a restart of the immune response against cancer cells, significantly improving survival in patients with metastatic melanoma and metastatic renal cell carcinoma (mRCC). It was hypothesized that proliferation of specific T cell clones may be associated with response to anti-PD1 therapy. The aim of this study was to analyze T cell repertoire in metastatic melanoma and mRCC patients treated with nivolumab and to correlate in with disease progression and overall survival.
Methods
Blood samples of 35 patients with metastatic melanoma and 21 patients with mRCC were evaluated and compared to 14 healthy controls. All melanoma patients were treated in 1st or 2nd line with nivolumab, all mRCC patients were treated with nivolumab in 2nd to 5th line after prior interferon α, sunitinib, pazopanib, everolimus or axitinib. Mononuclear cells were isolated from the peripheral blood on Histopaque. Cells were stained with directly labeled anti-CD3 PerCP-Cy5.5, anti-CD4 APC, anti-CD8 APC-Cy7 and anti-TCR FITC and PE antibodies. In total, 24 Vβ TCR families were evaluated. Measurement was performed by multicolor flow cytometry. Data were analyzed with Wilcoxon non-parametric test and principal component analysis.
Results
Significant changes in several TCR families (p<0.001) were confirmed: an increase of CD4+ cells or an increase of CD8+ cells were observed. In several patients, highly enriched individual populations of CD4+Vβ or CD8+Vβ cells were observed (>10% of CD3+). In these patients, median overall survival (OS) in 5 year observation was not reached, while in patients who did not show enriched Vβ cells, median OS was 3.15 years.
Conclusions
Significant changes in TCR repertoire were observed in melanoma and mRCC patients treated with nivolumab compared to healthy controls. Very high levels of CD4 and CD8 lymphocytes with defined TCR Vβ families were identified in approximately 40% of patients. Clonal expansion of CD4+ and CD8+ cells correlates with the response to treatment and overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Palacky University in Olomouc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1171P - Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: Options for new clinical opportunities
Presenter: Jorge Bartolome
Session: Poster session 13
1172P - Analysis of the microbiome of metastatic melanoma patients with complete response to immunotherapy
Presenter: Marin Golcic
Session: Poster session 13
1173P - NRAS mutation as an independent prognostic factor for resectable Chinese acral melanoma
Presenter: Yu Xu
Session: Poster session 13
1174P - Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801
Presenter: Eva Muñoz Couselo
Session: Poster session 13
1175P - Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients
Presenter: Judith Lijnsvelt
Session: Poster session 13
1176P - Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study
Presenter: Anna Czarnecka
Session: Poster session 13
1177P - Assessment of tumour burden reduction per photography vs magnetic resonance imaging in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg
Presenter: Ralf Gutzmer
Session: Poster session 13
1178P - Melanoma incidence rises for pediatrics: 15-year nationwide retrospective cohort study in Korea (2004-2019)
Presenter: Jisu Oh
Session: Poster session 13
1179P - The underestimated skin cancer risk after liver transplantation: A meta-analysis of 147154 patients
Presenter: Amr Ehab El-Qushayri
Session: Poster session 13